February 17th 2024
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Elucidating Additional Patient Subgroups Enhances Understanding of Cancer Biology
April 1st 2018<strong>IN THIS ISSUE OF </strong><em>The Journal of Targeted Therapies in Cancer</em>™, 2 articles in particular impressed me as reflective of the evolution and development of therapeutic possibilities for patients with recurrent and metastatic epithelial cancers. Although the 2 may initially seem to have distinct focuses, it is now becoming apparent that combinatorial strategies harnessing conventional modalities such as radiation therapy and immune stimulatory approaches may have additional value for this population of patients.
Read More
The Right Drug for the Right Patient: Moving Closer to Truly Personalized Medicine
April 1st 2018It is truly an exciting time in cancer research and drug development and it’s a privilege to be able to join Targeted Therapies in Oncology™ and assist an outstanding team of editors and writers to disseminate the most up-to-date, timely and clinically relevant information in this fast-paced era.
Read More
Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer
March 25th 2018According to study findings presented during the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers held in New Orleans March 24-27, clinical benefit has been found for women with recurrent ovarian cancer when using immune checkpoint inhibitors, but there was a higher rate of adverse events (AEs) than previously reported in other tumor types.
Read More
Breaking Down the Barriers to Immunotherapy in the Community
March 23rd 2018Although immuno-oncology is increasingly gaining strength within the community setting, familiarity with ever-changing indications, and patient and nonspecialist education are persistent issues for community oncology providers. These are a few of the many barriers currently standing in the way, based on interviews, focus groups, and surveys from 2017.
Read More
Arap and Pasqualini Join Oncology Leadership at Rutgers Cancer Institute of New Jersey
February 21st 2018The Rutgers Cancer Institute of New Jersey has announced 2 new additions to its team of oncology leaders. Wadih Arap, MD, PhD, will serve as the new director of the Rutgers Cancer Institute of New Jersey at University Hospital, and Renata Pasqualini, PhD, will serve as the chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School.
Read More